FibroGen, Inc. Exercises Exclusive License Option for HiFiBiOs CCR8 Program
December 20, 2021 at 08:00 am EST
FibroGen, Inc. and HiFiBiO Therapeutics announced an extension of their partnership with FibroGens exercise of an exclusive license option for HiFiBiOs anti-CCR8 monoclonal antibody program (HFB1011). Under the terms of the agreement, HiFiBiO will receive a $35 million upfront payment from FibroGen in addition to potential clinical, regulatory, and commercial milestones. HiFiBiO will also be eligible to receive royalties based upon net sales. FibroGen will have the sole right to develop all products in the CCR8 program worldwide. The development candidate is expected to enter clinical development in 2023.